<DOC>
	<DOCNO>NCT00002943</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy autologous bone marrow transplantation may help body kill tumor cell . PURPOSE : Phase II trial study effect high dos carboplatin , etoposide , cyclophosphamide follow autologous bone marrow transplantation patient relapse refractory germ cell cancer chemotherapy-sensitive solid tumor .</brief_summary>
	<brief_title>Carboplatin , Etoposide , Cyclophosphamide , Autologous Bone Marrow Transplantation Patients With Relapsed Refractory Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Investigate response rate , duration response , survival , time marrow reconstitution , toxicity two successive cycle high dose carboplatin , etoposide , cyclophosphamide chemotherapy ABMT patient relapse refractory germ cell cancer chemotherapy-sensitive solid tumor . - Further define pretransplant characteristic patient disease might influence outcome therapy . OUTLINE : Patients receive carboplatin etoposide 5 day cyclophosphamide 2 day prior ABMT . At day 60 follow ABMT , patient complete response ( CR ) partial response ( PR ) nonhematologic toxicity great grade 2 , second ABMT course give hematologic parameter criterion acceptable . If CR PR and/or nonhematologic toxicity exceeds grade 2 , second ABMT give . After ABMT patient follow disease progression death . PROJECTED ACCRUAL : Ten patient accrue pilot study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm , measurable germ cell cancer relapse refractory frontline therapy cisplatin etoposidecontaining chemotherapy Other chemotherapysensitive solid tumor eligible ( 06/11/97 ) Possibility residual mass represent benign teratoma must exclude Elevated serum tumor marker acceptable possibility falsepositive serum tumor marker sanctuary disease exclude Also eligible two four cycle conventional dose salvage chemotherapy , regardless response No CNS bone marrow involvement PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Greater 2 month Hematopoietic : Platelet count least 100,000/mm3 Neutrophil count least 1,500/mm3 Hepatic : Bilirubin , alkaline phosphatase , SGOT , SGPT le 3 time upper limit normal , unless due disease Renal : Creatinine le 1.5 time upper limit normal Creatinine clearance least 60 ml/min Cardiovascular : Ventricular ejection fraction least 45 % No uncontrolled severe cardiovascular disease include recent myocardial infarction , congestive heart failure , angina , lifethreatening arrhythmia , hypertension Pulmonary : DLCO spirometry great 50 % predict Other : Not HIV positive No active peptic ulcer No uncontrolled diabetes mellitus No active infection No previous concomitant malignancy curatively treat basal squamous cell carcinoma skin Not HBsAG positive PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior highdose carboplatin , etoposide , cyclophosphamide Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>extragonadal germ cell tumor</keyword>
</DOC>